Developer of injectable controlled release technologies designed to reduce the frequency of dosing for ocular therapies. The company’s injectable controlled release technologies provide therapeutic levels of sunitinib in preclinical studies reducing the potential frequency of dosing in neovascular age-related macular degeneration (nAMD) from every 4-8 weeks to as few as twice per year, enabling patients to access improved treatment of ocular disease.

IPO in September 2020 (NASDAQ: GRAY).

VISIT WEBSITE